Tetraphase Pharmaceuticals Inc. is closer to filing for FDA and EMA approval of eravacycline – the drug could become only the second tetracycline antibiotic cleared in more than 30 years – after reporting positive top-line data from the phase III IGNITE 1 study in complicated intra-abdominal infections (cIAIs) testing eravacycline against ertapenem. Read More
LONDON – The cost of developing a drug may be continuing to rise, but new figures show the forecast rate of return on that investment has increased for the first time since 2010. Read More
DUBLIN – Top-line data indicate the optimal dose of Poxel SA's first-in-class diabetes drug imeglimin hit the primary endpoint of a phase IIb dose-finding study in 382 patients with type 2 diabetes, with an average reduction in glycosylated hemoglobin (HbA1c) levels of 0.63 percent. Read More
As a sequel to last year's Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics Inc. that rendered isolated DNA ineligible for patenting, the Federal Circuit Wednesday struck down six more Myriad patent claims related to the BRCA 1 and 2 genes. Read More
HONG KONG – Research into the different mechanisms contributing to the development of antibiotic resistance may lead not only to the discovery of new methods for preventing the acquisition of microbial resistance, but also potentially may result in the development of new antibiotics, according to Japanese scientists. Read More
Padlock Therapeutics Inc., of Cambridge, Mass., said it raised $23 million in a series A financing led by Atlas Venture. The company plans to use the proceeds to deepen its understanding of the role of protein-arginine deiminases (PADs) in autoimmune disease and to advance its pipeline of PAD-directed therapeutics. Read More
Compugen Ltd., of Tel Aviv, Israel, initiated a multiyear research collaboration with Johns Hopkins University, School of Medicine, focusing on further evaluation of selected B7/CD28-like immune checkpoint candidates discovered by Compugen for the potential treatment of cancer. Read More
Eisai Ltd., of Hatfield, UK, said women with locally advanced or metastatic breast cancer (MBC) in Russia will have earlier access to Halaven (eribulin), indicated for patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Read More
Aldeyra Therapeutics Inc., of Lexington, Mass., submitted an investigational new drug application to the FDA to conduct phase II testing of NS2 for the treatment of noninfectious anterior uveitis. Read More
Pfizer Inc., of New York, disclosed top-line results from a double-blind phase III study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN). Read More
